HOMOLOGY DEADLINE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Homology Medicines, Inc. and Encourages Investors to Contact the Firm
Investors have until May 24, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
- Investors have until May 24, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
- Homology, a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases.
- On June 10, 2019, Homology issued a press release announcing that it had commenced enrollment of the HMI-102 Trial.
- The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies.